⚡ Why This Matters Right Now
As of July 1, 2026, Washington became the tenth state to require the UMPJE instead of the traditional state MPJE — joining Arizona, Iowa, North Carolina, Rhode Island (April 1), and Florida, Maryland, Montana, Nebraska, West Virginia (June 1). Ohio and Virginia follow October 1, and Kansas accepts both through April 2027. If you are seeking licensure in any of these states, the questions below reflect what your exam actually tests. Full transition details in our UMPJE Guide 2026.
How UMPJE Questions Differ From MPJE Questions
The traditional MPJE mixes federal law with one state's specific statutes — your CE hour counts, your PDMP system name, your technician ratios. The UMPJE deliberately strips out the state-specific trivia and tests legal principles that apply in nearly every U.S. jurisdiction: the Controlled Substances Act, DEA regulations, HIPAA, OBRA '90, the Orange Book, PPPA, and the DQSA.
That changes how you should practice. Skip anything asking about one state's exact rules and drill the universal framework instead. The 10 questions below are spread across the UMPJE's four content domains, in the same style NABP uses. Answer each one before opening the rationale — write your answer down first. If you got it right but were not confident, that counts as wrong for study purposes.
Domain 1: Controlled Substances
Question 1
A patient asks the pharmacist to partially fill her Schedule II oxycodone prescription, written today, because she cannot afford the full quantity. Under the Comprehensive Addiction and Recovery Act (CARA), how long does she have to collect the remaining portion?
A. 72 hours from the partial fill B. 7 days from the partial fill C. 30 days from the date the prescription was written D. 6 months from the date the prescription was written
✅ Answer: C — 30 days from the date written
CARA (2016) amended the CSA to allow partial fills of Schedule II prescriptions at the request of the patient or prescriber — the remainder must be dispensed within 30 days of the date the prescription was written, after which it is void. Candidates confuse this with the 72-hour rule, but that applies to a different situation: partial fills due to the pharmacy's inability to supply the full quantity. The 7-day figure belongs to emergency oral CII prescriptions (written follow-up deadline), and 6 months is the CIII–V refill window. Three different clocks, three different scenarios — the exam loves testing whether you can keep them straight.
Question 2
A pharmacy discovers a significant loss of hydrocodone tablets during a routine inventory count. What is the pharmacy's federal reporting obligation?
A. Notify the DEA in writing within one business day, then submit DEA Form 106 within 45 days B. Submit DEA Form 41 within 30 days C. Notify the state board of pharmacy only D. Document internally; no report needed unless theft is confirmed
✅ Answer: A — One business day notice + Form 106 within 45 days
Under the DEA's updated reporting rule (effective 2023), registrants must notify the DEA Field Division office in writing within one business day of discovering a theft or significant loss, then file the formal report electronically on DEA Form 106 within 45 calendar days. Form 41 is the distractor everyone falls for — that is for drug destruction, not loss. State board notification is usually also required, but the question asks about the federal obligation. And waiting for confirmation is exactly what the regulation says not to do: "significant loss" triggers the duty even without proven theft.
Question 3
A hospital pharmacy needs to order morphine injection (Schedule II) and diazepam (Schedule IV) from its wholesaler. Which ordering requirement applies?
A. Both require DEA Form 222 B. Morphine requires Form 222 or CSOS; diazepam requires only an ordinary invoice record C. Both may be ordered with an ordinary invoice D. Morphine requires Form 222; diazepam requires Form 224
✅ Answer: B — Form 222/CSOS for CII only
DEA Form 222 or its electronic equivalent CSOS is required only for Schedule I and II substances. Schedules III–V are ordered through normal commercial channels — the invoice itself becomes the required record, kept readily retrievable for two years. Form 224 is the distractor here: that is the registration application for a retail pharmacy, not an ordering document. If you remember one mapping for exam day: 222/CSOS = ordering CI–CII; 224 = pharmacy registration; 106 = theft/loss; 41 = destruction.
Question 4
A pharmacist receives a prescription for a high-dose opioid from a prescriber located three states away, for a patient paying cash, with a diagnosis code that does not match the drug. Under 21 CFR 1306.04, the pharmacist's "corresponding responsibility" means:
A. The prescriber alone is liable for an illegitimate prescription B. The pharmacist shares legal responsibility for ensuring the prescription was issued for a legitimate medical purpose C. The pharmacist must dispense but may counsel the patient D. The pharmacist must report the prescriber to the DEA before dispensing
✅ Answer: B — Shared responsibility for legitimacy
21 CFR 1306.04(a) places a corresponding responsibility on the dispensing pharmacist: a controlled substance prescription is valid only if issued for a legitimate medical purpose by a prescriber acting in the usual course of practice, and a pharmacist who knowingly fills an illegitimate one is subject to the same penalties as the issuer. Red flags — distance, cash payment, drug/diagnosis mismatch, pattern prescribing — require resolution before dispensing, not after. There is no duty to dispense (C is backwards), and reporting to the DEA (D) is not a prerequisite; the immediate obligation is simply to not fill until the concerns are resolved.
Domain 2: Pharmacy Practice
Question 5
Under OBRA '90, before dispensing a new prescription to a Medicaid patient, the pharmacist must perform which of the following?
A. Retrospective drug utilization review B. Prospective drug utilization review and an offer to counsel C. Mandatory face-to-face counseling D. Therapeutic interchange review with the prescriber
✅ Answer: B — Prospective DUR + offer to counsel
OBRA '90 requires a prospective DUR (screening for interactions, duplications, incorrect dosage, allergies) before each Medicaid prescription is dispensed, plus an offer to counsel — the patient may decline, which is why C is wrong; the counseling itself is not mandatory, the offer is. Retrospective DUR exists under OBRA too, but it is a state-level program review, not a dispensing prerequisite. Nearly every state has extended these requirements to all patients, which is exactly the kind of "broadly applicable state principle" the UMPJE tests without asking about any one state's statute.
Question 6
A prescriber writes for Drug X 10mg tablets. The pharmacy stocks a generic rated "AB" in the FDA Orange Book. Generic substitution is permissible because an AB rating indicates:
A. Pharmaceutical equivalence only B. The products contain the same active moiety in different dosage forms C. Therapeutic equivalence — pharmaceutical equivalence plus demonstrated bioequivalence D. The generic passed clinical efficacy trials
✅ Answer: C — Therapeutic equivalence
An AB rating in the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) means the generic is pharmaceutically equivalent (same active ingredient, strength, dosage form, route) and has demonstrated bioequivalence — together, therapeutic equivalence. "B"-rated products are the ones with unresolved equivalence problems. D is a classic trap: generics approved through ANDAs do not repeat clinical efficacy trials; that is the entire point of the Hatch-Waxman pathway. Substitution laws vary in whether they are mandatory or permissive, but the AB-rating principle applies everywhere.
Question 7
Which prescription product may NEVER be dispensed in a child-resistant container under the Poison Prevention Packaging Act, even at patient request?
A. Oral contraceptives in manufacturer packaging B. Sublingual nitroglycerin C. Prednisone dose packs D. There is no such product; any drug may use CR packaging
✅ Answer: B — Sublingual nitroglycerin
Sublingual nitroglycerin is the famous PPPA exemption that runs the opposite direction: because a patient having an anginal attack must access it in seconds, it is dispensed in its original non-child-resistant container — a safety-driven requirement, not merely an allowance. Oral contraceptives (A) are exempt but may still be dispensed in CR packaging. D misses the point entirely. Also remember who can waive CR packaging generally: the patient can give a blanket waiver for all prescriptions; the prescriber can waive only per-prescription.
Domain 3: Regulatory Structure & Oversight
Question 8
Federal law classifies a drug as Schedule V, but the state where the pharmacist practices classifies the same drug as Schedule III with stricter dispensing limits. The pharmacist should:
A. Follow federal law, which preempts state scheduling B. Follow the state's stricter classification C. Follow whichever law was enacted most recently D. Ask the state board for a written waiver
✅ Answer: B — The stricter law controls
This is the single most important principle in the regulatory-structure domain: when federal and state pharmacy law conflict, the pharmacist must satisfy both — which in practice means following the more stringent requirement. The CSA sets a federal floor, not a ceiling; states are free to schedule drugs more restrictively (many states schedule gabapentin, for example, while federally it remains unscheduled). Federal preemption (A) applies only where compliance with both is impossible, which is rare. Enactment date (C) is irrelevant, and no waiver mechanism (D) exists for this.
Domain 4: Drug Distribution & Medication Safety
Question 9
A compounding operation registers with the FDA, follows CGMP, and produces compounded sterile preparations in bulk without patient-specific prescriptions for sale to hospitals. Under the Drug Quality and Security Act, this describes a:
A. 503A traditional compounding pharmacy B. 503B outsourcing facility C. Repackager under the DSCSA D. Manufacturer requiring a New Drug Application
✅ Answer: B — 503B outsourcing facility
The DQSA (2013, passed after the NECC meningitis outbreak) split compounding into two tracks. 503A pharmacies compound pursuant to patient-specific prescriptions and follow USP standards under state board oversight. 503B outsourcing facilities voluntarily register with the FDA, follow full CGMP, and may compound without patient-specific prescriptions for office and hospital use. C confuses distribution law (DSCSA track-and-trace) with compounding law, and D is wrong because 503B facilities are explicitly exempt from the NDA requirement. Know both tracks cold — this distinction appears on virtually every administration.
Question 10
The FDA announces a recall of a blood pressure medication after discovering a nitrosamine impurity with a reasonable probability of causing serious adverse health consequences. This is classified as a:
A. Class I recall B. Class II recall C. Class III recall D. Market withdrawal
✅ Answer: A — Class I recall
Recall classes are ranked by hazard, and the wording in the stem is lifted almost verbatim from the FDA's definition: Class I = reasonable probability of serious adverse health consequences or death. Class II = temporary or reversible harm (or remote probability of serious harm); Class III = unlikely to cause harm (think labeling defects). A market withdrawal (D) is the company's own action for a minor issue not subject to FDA legal action — different animal. Pharmacists' recall responsibilities (quarantine stock, contact patients for Class I) flow directly from these classifications, so the exam tests them in scenario form exactly like this.
How Did You Score?
| Score | What It Means | Next Step |
|---|---|---|
| 9–10 | Exam-ready on federal fundamentals | Move to timed mixed practice and the official Pre-UMPJE |
| 7–8 | Solid base with specific gaps | Re-read the rationales you missed, then drill that domain |
| 5–6 | Foundation needs work | Work through the federal law guide and CSA deep-dive first |
| <5 | Too early for practice questions | Start with the UMPJE study guide and a structured study plan |
Where to Get More UMPJE Practice
- The official Pre-UMPJE — NABP's 40-question practice exam, purchased through your e-Profile at nabp.pharmacy. Worth it in your final week because it mirrors the real question style.
- Our free quizzes — the federal law, controlled substances, and compounding law quizzes all test UMPJE-relevant universal principles.
- Full question banks — PharmacyExam.com covers the UMPJE content domains plus all 51 traditional MPJE jurisdictions with thousands of questions and legal rationales, updated for 2026.